Echo Therapeutics enhances its needle-free Symphony tCGM biosensor

Oct 30 2009

Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has made significant advances to the development of its needle-free Symphony tCGM biosensor. The biosensor replaces the prototype two-piece biosensor used in earlier clinical trials and is designed to offer a one-piece, cost-effective, single-use biosensor with improved performance for use by consumers and healthcare providers.

"We are extremely pleased to announce this next step in the product development work on our one-piece biosensor, a critical component of Symphony, our needle-free, continuous glucose monitoring technology," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "This next generation one-piece biosensor introduces new materials and a more effective geometrical construction and replaces the prior prototype two-piece biosensor used in earlier clinical trials. We believe that this new one-piece design will significantly reduce manufacturing costs, enabling the Company to offer a low-cost product. We also believe that this design will lead to improved continuous monitoring performance since a one-piece biosensor eliminates a primary source of the motion artifact seen with the earlier prototype two-piece biosensor. We look forward to testing this new and improved biosensor in a clinical trial in the near term and confirming the performance attributes observed in internal testing."

The new one-piece biosensor utilizes new materials and effective geometry design. It is intended to be a cost-effective product that allows for advanced continuous glucose monitoring performance for consumers and healthcare providers.